| Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer DA Mehta, JW Hay Gynecologic oncology 132 (3), 677-683, 2014 | 57 | 2014 |
| Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 … DA Mehta, E Cohen, M Charafeddine, DE Cohen, Y Bao, YS Gonzalez, ... Infect Dis Ther, 2017 | 30 | 2017 |
| Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real‐world data from a large healthcare provider C Weil, D Mehta, G Koren, B Pinsky, JC Samp, G Chodick, V Shalev Journal of viral hepatitis 25 (2), 144-151, 2018 | 14 | 2018 |
| Impact of telehealth on health care resource utilization during the COVID-19 pandemic P Arora, D Mehta, J Ha Journal of Comparative Effectiveness Research 11 (5), 301-309, 2022 | 11 | 2022 |
| A budget impact model of hemophilia bypassing agent prophylaxis relative to recombinant factor VIIa on-demand DA Mehta, AO Oladapo, JD Epstein, AR Novack, EJ Neufeld, JW Hay Journal of Managed Care & Specialty Pharmacy 22 (2), 149-157, 2016 | 8 | 2016 |
| Analysis of the impact of HIV co-infection on hepatitis c treatment effectiveness for patients using new direct-acting antivirals J McGinnis, J McCombs, D Mehta, S Fox, I Tonnu-Mihara Journal of Hepatology 2 (64), S219-S220, 2016 | 8 | 2016 |
| Pan-genotypic hepatitis C treatment with glecaprevir and pibrentasvir for 8 weeks resulted in improved cardiovascular and metabolic outcomes and stable renal function: A post … TT Tran, D Mehta, F Mensa, C Park, Y Bao, Y Sanchez Gonzalez Infectious Diseases and Therapy 7, 473-484, 2018 | 7 | 2018 |
| Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir … T Tran, D Mehta, A Goldstein, E Cohen, Y Bao, YS Gonzalez Journal of Hepatology 1 (66), S302, 2017 | 7 | 2017 |
| Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures J Hixson, B Gidal, A Pikalov, Y Zhang, D Mehta, D Blum, D Cantu, ... Epilepsy Research 171, 106561, 2021 | 6 | 2021 |
| Impact of early initiation of eslicarbazepine acetate on economic outcomes among patients with focal seizure: results from retrospective database analyses D Mehta, M Davis, AJ Epstein, B Wensel, T Grinnell, GR Williams Neurology and Therapy 9, 585-598, 2020 | 6 | 2020 |
| Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes D Mehta, M Davis, A Epstein, A Lee Neurology and Therapy, 2020 | 6 | 2020 |
| Effect of ombitasvir/paritaprevir/ritonavir+ dasabuvir regimen on health‐related quality of life for patients with hepatitis C S Saab, D Mehta, S Hudgens, N Grunow, Y Bao, B Pinsky Liver International 38 (8), 1377-1394, 2018 | 5 | 2018 |
| Comparative economic outcomes in patients with focal seizure initiating first-line eslicarbazepine acetate monotherapy versus generic antiseizure drugs D Mehta, M Davis, AJ Epstein, B Wensel, T Grinnell, GR Williams ClinicoEconomics and Outcomes Research, 251-261, 2021 | 4 | 2021 |
| Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures … JA Cramer, S Colman, KP Anastassopoulos, T Grinnell, D Mehta, ... Epilepsy & Behavior 112, 107312, 2020 | 4 | 2020 |
| Characteristics of Adult Patients With Focal Seizure Receiving Eslicarbazepine Acetate Therapy in Routine Clinical Practice: Evidence From a Large US Commercial Claims Database BN Darshan Mehta, Andrew Lee, Jason Simeone, Krithika Rajagopalan, Robert ... American Epilepsy Society 2018, 2018 | 4* | 2018 |
| Pan-genotypic hepatitis C treatment with glecaprevir plus pibrentasvir resulted in improvement in cardiovascular and metabolic extrahepatic manifestations and stable renal … TT Tran, D Mehta, FJ Mensa, C Park, Y Sanchez Hepatology 66, 633A-633A, 2017 | 4 | 2017 |
| Systematic literature review of key outcomes used to assess adjunctive treatments for Parkinson's disease A Thach, M Zichlin, M Peddle, M Du, A Lerner, N Kirson, A Bowling, ... MOVEMENT DISORDERS 37, S357-S357, 2022 | 3 | 2022 |
| PMU5 IMPACT of telehealth utilization during the COVID-19 pandemic on health care resource utilization P Arora, J Ha, D Mehta Value in Health 24, S145, 2021 | 3 | 2021 |
| Healthcare resource utilization pre-and post-initiation of eslicarbazepine acetate among pediatric patients with focal seizure: evidence from routine clinical practice D Mehta, M Davis, AJ Epstein, GR Williams ClinicoEconomics and Outcomes Research, 379-387, 2020 | 3 | 2020 |
| Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’episodes A Thach, ML Zichlin, N Kirson, K Yang, K Gaburo, E Pappert, D Mehta, ... Journal of Comparative Effectiveness Research 11 (4), 285-295, 2022 | 2 | 2022 |
Andrew J EpsteinMedicus EconomicsVerified email at medicuseconomics.com
